Jefferies Highlights Yutrepia’s Market Edge in Supporting a Buy on Liquidia (LQDA)

Liquidia Corp. (NASDAQ:LQDA) is one of the most shorted stocks right now. On August 15, Jefferies analyst Amy Li initiated coverage on Liquidia Technologies Inc. (NASDAQ:LQDA) with a Buy rating and a $43 price target. Liquidia Technologies is a subsidiary and operating arm of Liquidia Corporation.

Li pointed to strong early traction for the company’s lead product, Yutrepia, which is gaining prescriptions and patients at a pace ahead of expectations. She projects Yutrepia could generate $108 million in revenue by FY 2025, well above consensus estimates.

Jefferies Highlights Yutrepia’s Market Edge in Supporting a Buy on Liquidia (LQDA)

The analyst highlighted that Yutrepia stands out because it reaches effective doses more quickly without increasing the chance of coughing, a clear edge over other treatments for pulmonary hypertension and interstitial lung disease.

While ongoing patent litigation creates uncertainty, the analyst believes that positive feedback from physicians and encouraging clinical data support its prospects for broader market adoption. She expects these dynamics to drive profitability by the end of 2025, which supports the bullish view on Liquidia Corp. (NASDAQ:LQDA).

Liquidia Corp. (NASDAQ:LQDA) is a biopharmaceutical company focused on developing and commercializing therapies for rare pulmonary diseases.

While we acknowledge the potential of LQDA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LQDA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Stocks for a 20 Year Long-Term Stock Portfolio and 12 Overlooked Large-Cap Stocks with Low Multiples.

Disclosure: None. This article is originally published at Insider Monkey.